249 related articles for article (PubMed ID: 8319372)
1. Growth hormone releasing hormone priming increases growth hormone secretion in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Villamil F; Astorga R; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1993 Apr; 38(4):399-403. PubMed ID: 8319372
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
[TBL] [Abstract][Full Text] [Related]
3. Pyridostigmine enhances even if it does not normalize the growth hormone responses to growth hormone-releasing hormone in patients with Cushing's disease.
Giustina A; Bossoni S; Bodini C; Ferrari C; Pizzocolo G; Scalvini T; Schettino M; Wehrenberg WB
Horm Res; 1991; 35(3-4):99-103. PubMed ID: 1806475
[TBL] [Abstract][Full Text] [Related]
4. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
[TBL] [Abstract][Full Text] [Related]
5. Effect of withdrawal of somatostatin plus growth hormone (GH)-releasing hormone as a stimulus of GH secretion in Cushing's syndrome.
Leal-Cerro A; Soto A; MartÃnez MA; Alvarez P; Isidro L; Casanueva FF; Dieguez C; Cordido F
Clin Endocrinol (Oxf); 2002 Dec; 57(6):745-9. PubMed ID: 12460324
[TBL] [Abstract][Full Text] [Related]
6. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on growth hormone (GH) responses to GH-releasing hormone in patients with Cushing's syndrome.
Leal-Cerro A; Pereira JL; Garcia-Luna PP; Astorga R; Cordido F; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1990 Aug; 33(2):291-5. PubMed ID: 2225484
[TBL] [Abstract][Full Text] [Related]
7. Enhanced growth hormone (GH) responsiveness to GH-releasing hormone after dietary restriction in patients with Cushing's syndrome.
Leal-Cerro A; Venegas E; Garcia-Pesquera F; Jimenez LM; Astorga R; Casanueva FF; Dieguez C
Clin Endocrinol (Oxf); 1998 Jan; 48(1):117-21. PubMed ID: 9509077
[TBL] [Abstract][Full Text] [Related]
8. Different effects of pyridostigmine on growth hormone (GH) response to GH-releasing hormone in endogenous and exogenous hypercortisolemic patients.
Borges MH; Castro RC; Kater CE; Lengyel AM
Braz J Med Biol Res; 1993 Nov; 26(11):1191-200. PubMed ID: 7907904
[TBL] [Abstract][Full Text] [Related]
9. Pyridostigmine partially reverses dexamethasone-induced inhibition of the growth hormone response to growth hormone-releasing hormone.
Trainer PJ; Kirk JM; Savage MO; Grossman AB; Besser GM
J Endocrinol; 1992 Sep; 134(3):513-7. PubMed ID: 1357070
[TBL] [Abstract][Full Text] [Related]
10. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
[TBL] [Abstract][Full Text] [Related]
11. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
12. Assessment of GH reserve before and after successful treatment of adult patients with Cushing's syndrome.
Tzanela M; Karavitaki N; Stylianidou C; Tsagarakis S; Thalassinos NC
Clin Endocrinol (Oxf); 2004 Mar; 60(3):309-14. PubMed ID: 15008995
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of impaired growth hormone secretion in patients with Cushing's disease.
Takahashi H; Bando H; Zhang C; Yamasaki R; Saito S
Acta Endocrinol (Copenh); 1992 Jul; 127(1):13-7. PubMed ID: 1519417
[TBL] [Abstract][Full Text] [Related]
14. Effect of galanin on the growth hormone (GH) response to GH-releasing hormone in patients with Cushing's disease.
Giustina A; Bossoni S; Bussi AR; Pozzi A; Wehrenberg WB
Endocr Res; 1993 Mar; 19(1):47-56. PubMed ID: 7681769
[TBL] [Abstract][Full Text] [Related]
15. Acute pharmacological reduction of plasma free fatty acids enhances the growth hormone (GH)-releasing hormone-mediated GH secretion in patients with Cushing's syndrome.
Leal-Cerro A; Jimenez LM; Astorga R; Fernandez-Lopez I; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1997 Sep; 82(9):3165-8. PubMed ID: 9284763
[TBL] [Abstract][Full Text] [Related]
16. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
[TBL] [Abstract][Full Text] [Related]
17. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
[TBL] [Abstract][Full Text] [Related]
18. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
[TBL] [Abstract][Full Text] [Related]
19. Radiation and neuroregulatory control of growth hormone secretion.
Ogilvy-Stuart AL; Wallace WH; Shalet SM
Clin Endocrinol (Oxf); 1994 Aug; 41(2):163-8. PubMed ID: 7923820
[TBL] [Abstract][Full Text] [Related]
20. Activation of cholinergic tone by pyridostigmine reverses the inhibitory effect of corticotropin-releasing hormone on the growth hormone-releasing hormone-induced growth hormone secretion.
Corsello SM; Tofani A; Della Casa S; Sciuto R; Rota CA; Colasanti S; Bini A; Barini A; Barbarino A
Acta Endocrinol (Copenh); 1992 Feb; 126(2):113-6. PubMed ID: 1543015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
